4/17
03:26 pm
aeon
AEON Biopharma, Inc. (NASDAQ: AEON) had its "buy" rating re-affirmed by analysts at HC Wainwright. They now have a $18.00 price target on the stock.
Low
Report
AEON Biopharma, Inc. (NASDAQ: AEON) had its "buy" rating re-affirmed by analysts at HC Wainwright. They now have a $18.00 price target on the stock.
3/30
10:53 pm
aeon
CORRECTION -- AEON Biopharma Announces Redemption of Public Warrants
High
Report
CORRECTION -- AEON Biopharma Announces Redemption of Public Warrants
3/29
04:15 pm
aeon
AEON Biopharma Announces Redemption of Public Warrants
High
Report
AEON Biopharma Announces Redemption of Public Warrants
3/29
03:45 pm
aeon
AEON Biopharma Reports Fourth Quarter and Full Year 2023 Financial Results
High
Report
AEON Biopharma Reports Fourth Quarter and Full Year 2023 Financial Results
3/19
04:30 pm
aeon
AEON Biopharma Announces Clinical Update and Productive End-of-Phase 2 Meeting with FDA on ABP-450 (prabotulinumtoxinA) for the Preventive Treatment of Migraine
Medium
Report
AEON Biopharma Announces Clinical Update and Productive End-of-Phase 2 Meeting with FDA on ABP-450 (prabotulinumtoxinA) for the Preventive Treatment of Migraine
3/19
04:29 pm
aeon
AEON Biopharma Announces $15 Million Financing Transaction and Termination of Forward Purchase Agreements
Medium
Report
AEON Biopharma Announces $15 Million Financing Transaction and Termination of Forward Purchase Agreements